Human papillomavirus and Papanicolaou tests to screen for cervical cancer

New England Journal of Medicine

Volumn 357, Issue 16, 2007, Pages 1589-1597

  Naucler, Pontus ^a   Ryd, Walter ^b   Törnberg, Sven ^c   Strand, Anders ^e   Wadell, Göran ^f   Elfgren, Kristina ^c   Rådberg, Thomas ^b   Strander, Björn ^b   Forslund, Ola ^a   Hansson, Bengt Göran ^a   Rylander, Eva ^d   Dillner, Joakim ^a  

^a LUND UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d DANDERYD HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COLPOSCOPY; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PATIENT REFERRAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERUS BIOPSY; WART VIRUS;

EID: 35349004609     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa073204     Document Type: Article

References (28)

1. Bergström R, Sparén P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer 1999;81:159-66.
2. Cancer incidence in Sweden 2005. Stockholm: National Board of Health and Welfare (Socialstyrelsen), 2007.
3. Wallin KL, Wiklund F, Angström T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-8.
4. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
5. Bulkmans NW, Rozendaal L, Voorhorst FJ, Snijders PJ, Meijer CJ. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer 2005;92:1800-2.
6. Hoyer H, Scheungraber C, Kuehne-Heid R, et al. Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting. Int J Cancer 2005;116:136-43.
7. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52.
8. Clavel C, Cucherousset J, Lorenzato M, et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions. Br J Cancer 2004;90:1803-8.
9. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-9.
10. Arbyn M, Anttila A, Jordan J, et al. European guidelines for quality assurance in cervical cancer screening. Luxembourg: European Commission, Office for Official Publication of the European Communities, 2007.
11. Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94-101.
12. Kitchener HC, Almonte M, Wheeler P, et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006;95:56-61.
13. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005;93:862-7.
14. Mayrand MH, Duarte-Franco E, Coutlée F, et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian Cervical Cancer Screening Trial (CCCaST). Int J Cancer 2006;119:615-23.
15. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006;7:547-55.
16. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006;98:765-74.
17. Cuschieri KS, Cubie HA, Whitley MW, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004;57:68-72.
18. Evander M, Edlund K, Gustafsson A, et al. Human papillomavirus infection is transient in young women: a populationbased cohort study. J Infect Dis 1995;171:1026-30.
19. Hagmar B, Kalantari M, Skyldberg B, et al. Human papillomavirus in cell samples from Stockholm Gynecologic Health Screening. Acta Cytol 1995;39:741-5.
20. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-101.
21. Koss LG, ed. Diagnostic cytology and its histopathologic basis. 3d ed. Philadelphia: Lippincott, 1979.
22. Elfgren K, Rylander E, Rådberg T, et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol 2005;193:650-7.
23. de Roda Husman AM, Walboomers JM, Hopman E, et al. HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern. J Med Virol 1995;46:97-102.
24. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:791-5.
25. Forslund O, Antonsson A, Edlund K, et al. Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol 2002;66:535-41. [Erratum, J Med Virol 2002;67:467.]
26. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven, 1998.
27. Day NE. Overdiagnosis and breast cancer screening. Breast Cancer Res 2005;7:228-9.
28. The ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-92.